Aandelen in “Farmaceutische Producten: Generisch”

Aandeel Datum Koers Evolutie
vlag Benchmark Holdings plc 21/05 22,300 GBX
-0,45% 		-0,45%
vlag BridgeBio Pharma Inc 21/05 32,840 USD
-2,58% 		-2,58%

Nieuws over “Farmaceutische Producten: Generisch”

20/05 · Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt · Persbericht

20/05 · Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt · Persbericht

20/05 · Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy · Persbericht

19/05 · Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031 · Persbericht

19/05 · Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes · Persbericht

16/05 · Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy · Persbericht

12/05 · Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy · Persbericht

7/05 · Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City · Persbericht

7/05 · Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved · Persbericht

5/05 · Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) · Persbericht

17/04 · Hikma acquires Novugen's FDA-approved ANDA for trametinib · Persbericht

7/04 · Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States · Persbericht

7/04 · Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention · Persbericht

31/03 · New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable · Persbericht

27/03 · Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 · Persbericht

27/03 · Teva Releases Q1 2025 Aide Memoire · Persbericht

27/03 · Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia · Persbericht

27/03 · Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM · Persbericht

3/03 · Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March · Persbericht

27/02 · 2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals · Persbericht

25/02 · Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder · Persbericht

Mijn selecties